Resistance to allergy medication is a concern for many people managing long-term conditions such as allergic rhinitis, urticaria, or asthma. Over months or years, treatments that once provided reliable relief can seem less effective — but true pharmacological resistance is rarely the cause. More often, reduced efficacy reflects poor inhaler technique, increased allergen exposure, evolving sensitivities, or unrecognised comorbidities. Understanding the real reasons behind treatment failure is essential for finding a safe, effective long-term strategy. This article explores how common allergy medications work, why they may appear to stop working, and what options are available through the NHS when standard treatments are no longer sufficient.

Why Allergy Medications May Become Less Effective Over Time

Many people who rely on allergy medications notice that, after months or years of use, their symptoms seem less well controlled than they once were. This experience is relatively common and can be frustrating, particularly for those managing chronic conditions such as allergic rhinitis, urticaria, or asthma. Understanding why this happens is the first step towards finding a more effective long-term strategy.

In pharmacological terms, true 'resistance' — where the body's receptors stop responding to a drug entirely — is uncommon with most allergy medications. True pharmacological tolerance to antihistamines or intranasal corticosteroids (INCS) is rare; when these treatments appear to stop working, the cause is more often related to poor adherence, incorrect technique, increased allergen exposure, or the development of comorbid conditions. A phenomenon known as tachyphylaxis — a rapid reduction in response following repeated doses — is more specifically associated with certain nasal decongestant sprays, such as xylometazoline, where rebound congestion (rhinitis medicamentosa) can develop after prolonged use. UK guidance advises that topical nasal decongestants should not be used for more than 7 days to avoid this effect.

It is also important to recognise that what appears to be reduced efficacy may actually reflect a change in the underlying allergy itself. Allergic sensitisation can evolve — new allergens may be acquired, existing sensitivities may worsen, or the pattern of exposure may shift seasonally or environmentally. In these cases, the medication has not truly failed; rather, the clinical picture has changed. A thorough reassessment — including review of inhaler and spray technique, allergen exposure, and consideration of skin prick or specific IgE testing — is often more informative than simply switching or increasing medication doses.

Types of Allergy Medication and How They Work

Allergy medications work through several distinct mechanisms, and understanding these helps explain both their benefits and their limitations over time.

Antihistamines are among the most widely used allergy treatments. They work by blocking H1 histamine receptors, thereby reducing symptoms such as sneezing, itching, and a runny nose. First-generation antihistamines (e.g., chlorphenamine) cross the blood–brain barrier and can cause sedation. Second-generation antihistamines (e.g., cetirizine, loratadine) are preferred for regular use due to their improved side-effect profile and are available over the counter. Fexofenadine is also a second-generation antihistamine, though it is worth noting that the 180 mg strength remains prescription-only in the UK. These agents are recommended by NICE for the management of allergic rhinitis.

Intranasal corticosteroids (e.g., beclometasone, fluticasone) are considered first-line treatment for moderate-to-severe allergic rhinitis by NICE. They reduce local airway inflammation by suppressing the release of inflammatory mediators. Unlike decongestants, they do not cause rebound congestion and are safe for long-term use at recommended doses. Common local side effects include nasal irritation and epistaxis; patients should be advised to use the lowest effective dose, particularly in children, and to direct the spray away from the nasal septum.

Intranasal antihistamines (e.g., azelastine nasal spray) offer a useful alternative or add-on for allergic rhinitis, with a faster onset of action than oral antihistamines. A combination nasal spray containing azelastine and fluticasone is available in the UK and has good evidence for symptom control in moderate-to-severe allergic rhinitis when monotherapy is insufficient.

Ipratropium bromide nasal spray may be considered for patients in whom watery rhinorrhoea is the predominant symptom and is not adequately controlled by other agents.

Leukotriene receptor antagonists such as montelukast block the action of leukotrienes — inflammatory chemicals involved in allergic responses. In the context of allergic rhinitis, montelukast is not a first-line treatment; it may be considered as an add-on option, particularly where rhinitis coexists with asthma or when standard therapy has proved inadequate. The MHRA has issued a Drug Safety Update highlighting the potential for neuropsychiatric side effects with montelukast, including sleep disturbances, anxiety, depression, and suicidal ideation. Patients and carers should be counselled about these risks before starting treatment and advised to seek medical attention if such symptoms develop. Suspected adverse reactions should be reported via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk).

Mast cell stabilisers (e.g., sodium cromoglicate) prevent the release of histamine from mast cells and are available as eye drops or nasal sprays. They are generally well tolerated but require regular use to be effective.

Common Reasons Your Allergy Treatment Stops Working

Before concluding that resistance to allergy medication has developed, it is worth considering several practical and clinical explanations for reduced treatment efficacy.

Poor adherence or incorrect technique is one of the most common reasons allergy treatments underperform. Intranasal corticosteroid sprays, for example, must be directed away from the nasal septum and used consistently every day to achieve their full anti-inflammatory effect — maximal benefit may take several days of regular use to become apparent. Many patients use them only when symptoms flare, rather than as a preventative daily treatment, which significantly reduces their effectiveness. NHS guidance on correct nasal spray technique is available online and is worth reviewing.

Increased allergen exposure is another key factor. A particularly high pollen season, a new pet in the household, or a change in living or working environment can overwhelm a previously adequate treatment regimen. In these cases, the medication itself has not changed — the burden on the immune system has increased.

Other important considerations include:

• Development of new allergic sensitivities not covered by the current treatment

• Comorbid conditions such as nasal polyps, chronic rhinosinusitis, or non-allergic rhinitis that mimic or worsen allergic symptoms

• Medication interactions that may reduce drug absorption or efficacy — for example, fexofenadine absorption can be significantly reduced by grapefruit, orange, or apple juice, and by antacids containing aluminium or magnesium; these should be avoided around the time of dosing

• Rebound congestion (rhinitis medicamentosa) from prolonged use of topical nasal decongestants — UK guidance advises these should not be used for more than 7 days

Finally, it is worth noting that some individuals may have been misdiagnosed initially. Conditions such as vasomotor rhinitis or food intolerance can present similarly to allergic disease but do not respond to antihistamines or corticosteroids in the same way. A formal allergy assessment, including skin prick testing or specific IgE blood tests, can help clarify the diagnosis.

When to Speak to a GP or Allergy Specialist

Whilst many allergy symptoms can be managed effectively with over-the-counter treatments, there are clear circumstances in which professional medical advice should be sought. Recognising these is important for patient safety and for preventing unnecessary suffering.

You should contact your GP if:

• Your symptoms are no longer controlled by antihistamines or intranasal corticosteroids that previously worked well

• You are using nasal decongestant sprays for more than 7 days, as this risks rebound congestion

• Your allergy symptoms are significantly affecting your sleep, work, or quality of life

• You develop new symptoms such as facial pain, loss of smell, or persistent nasal blockage, which may suggest sinusitis or nasal polyps

• You experience side effects from your current medication — particularly neuropsychiatric symptoms (such as sleep disturbance, anxiety, low mood, or unusual behaviour) if taking montelukast

• You notice unilateral (one-sided) nasal obstruction, blood-stained nasal discharge, recurrent nosebleeds, visual disturbance, or severe facial pain or swelling — these symptoms require prompt assessment to exclude other causes

A referral to an NHS allergy specialist is appropriate when first-line treatments have failed, when the diagnosis is uncertain, or when allergen immunotherapy is being considered. NICE guidance supports referral for patients with severe or poorly controlled allergic rhinitis, occupational allergies, or those who may benefit from structured allergy testing. Referral to ENT may be more appropriate where nasal polyps, chronic rhinosinusitis, or unilateral nasal symptoms are suspected.

In cases of anaphylaxis or severe allergic reactions, emergency services (999) should be contacted immediately. Patients at risk of anaphylaxis should carry their prescribed adrenaline auto-injector (AAI) — such as an EpiPen or Jext — at all times. If anaphylaxis occurs: use the AAI, call 999, lie down (or sit upright if breathing is difficult), and administer a second dose after 5 minutes if there is no improvement. A written emergency action plan should be provided by the allergy team. Any suspected adverse drug reactions should be reported via the MHRA Yellow Card scheme.

Alternative and Combination Treatments Available on the NHS

When standard allergy medications are no longer providing adequate relief, a range of alternative and combination approaches are available through the NHS, guided by NICE and specialist allergy services.

Combination pharmacotherapy is a practical strategy used in clinical practice. For example, adding an intranasal corticosteroid to a second-generation antihistamine, or using the azelastine/fluticasone combination nasal spray, may provide better symptom control than either agent alone in moderate-to-severe allergic rhinitis. Leukotriene receptor antagonists such as montelukast may be considered as add-on therapy where rhinitis coexists with asthma, in line with NICE guidance. Any escalation of treatment should follow a stepwise approach guided by symptom severity and response.

Allergen immunotherapy (AIT) — also known as desensitisation — is the only treatment that modifies the underlying allergic disease rather than simply managing symptoms. It is specialist-initiated and requires confirmed IgE-mediated allergy and inadequate control on optimal pharmacotherapy. It involves the gradual introduction of increasing doses of an allergen, either via subcutaneous injections (SCIT) or sublingual tablets or drops (SLIT), to induce immune tolerance.

NICE has approved sublingual grass pollen immunotherapy products (e.g., Grazax, licensed for ages 5–65 years; ITULAZAX, licensed for adults) for patients with severe grass pollen allergic rhinitis inadequately controlled by antihistamines and intranasal corticosteroids. Sublingual house dust mite immunotherapy (e.g., Acarizax) is also available for selected adults with confirmed HDM allergy; it should not be used in patients with uncontrolled asthma. Patients receiving SCIT should carry an AAI during and after clinic visits, as per clinic protocol. All immunotherapy should be initiated and supervised by a specialist.

For patients with chronic spontaneous urticaria unresponsive to standard-dose antihistamines, the recommended stepwise approach is: first increase the non-sedating antihistamine to up to four times the standard daily dose, before escalating to the biologic therapy omalizumab (Xolair) — a monoclonal antibody targeting IgE — which is available on the NHS for eligible patients in line with NICE technology appraisal guidance.

Non-pharmacological measures, such as allergen avoidance strategies, nasal saline irrigation, and air filtration, can also complement medical treatment and reduce overall allergen burden.

Managing Long-Term Allergies Safely and Effectively

Living with a long-term allergy requires an ongoing, proactive approach rather than reactive symptom management. With the right strategy, most people can achieve good symptom control and maintain a good quality of life.

Periodic review of your allergy management plan is important. Allergic conditions can change over time, and a treatment that was appropriate previously may no longer be the best option. Reviews with a GP or allergy nurse are recommended when symptoms are poorly controlled, when medications change, or when allergy is having a significant impact on quality of life — rather than on a fixed universal schedule.

Allergen avoidance remains a cornerstone of long-term allergy management. Practical measures include:

• Using allergen-impermeable mattress and pillow covers for house dust mite allergy

• Monitoring pollen forecasts and limiting outdoor activity on high-pollen days

• Keeping windows closed during peak pollen seasons

• Avoiding known food triggers and reading ingredient labels carefully

It is also important to use medications correctly and consistently. Intranasal corticosteroids take several days of daily use to reach their full anti-inflammatory effect and should be used throughout the allergy season, not just when symptoms are severe. Direct the spray away from the nasal septum and follow the technique guidance provided with the product or available from the NHS. Patients should be counselled on correct inhaler and spray technique to maximise drug delivery.

Mental health and wellbeing should not be overlooked. Chronic allergic conditions are associated with increased rates of anxiety, sleep disturbance, and reduced productivity. Addressing these aspects as part of a holistic management plan — including signposting to NHS mental health support where appropriate — contributes to better overall outcomes.

If you experience any suspected side effects from your allergy medication, you can report these directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Open communication with your healthcare team remains the most effective tool in managing allergy treatment over the long term.

Frequently Asked Questions